# OnCo record paper-cpx-351-study-301-lancet-je-jco-2018 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-cpx-351-study-301-lancet-je-jco-2018/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-cpx-351-study-301-lancet-je-jco-2018" ;
  schema:name "CPX-351 versus 7+3 chemotherapy in older adults with newly diagnosed secondary acute myeloid leukaemia"@en ;
  schema:description "A liposomal formulation locking cytarabine and daunorubicin in a fixed ratio lengthened survival compared with standard 7+3 chemotherapy in patients aged 60 to 75 with secondary or therapy-related acute myeloid leukaemia, and more of them reached transplant."@en ;
  schema:url <https://onco.cc/key-papers/paper-cpx-351-study-301-lancet-je-jco-2018/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.2017.77.6112>, <https://pubmed.ncbi.nlm.nih.gov/30024784/> ;
  schema:sameAs <https://doi.org/10.1200/JCO.2017.77.6112> ;
  schema:datePublished "2018"^^xsd:gYear ;
  schema:author "Lancet JE, Uy GL, Cortes JE, et al." ;
  onco:cancers <https://onco.cc/cancers/aml-secondary/> ;
  onco:drugs <https://onco.cc/drugs/cytarabine/>, <https://onco.cc/drugs/daunorubicin/> ;
  onco:journals <https://onco.cc/journals/jco/> .